Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 5/20 | 0.42 |
| ▸ | HRH1 | P35367 | 5/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD5 | P21918 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1917028 | 1.00 | HTR2B (0.42) | HTR2BHRH1KCNH2ALDH1A1LMNA | |
| SCHEMBL1917023 | 1.00 | HTR2B (0.42) | HTR2BHRH1KCNH2ALDH1A1LMNA | |
| SCHEMBL4360936 | 0.91 | AKR1B1 (0.45) | HTR2BHRH1KCNH2ALDH1A1LMNA | |
| SCHEMBL8135265 | 0.91 | AKR1B1 (0.45) | HTR2BHRH1KCNH2ALDH1A1LMNA | |
| SCHEMBL4360929 | 0.91 | AKR1B1 (0.45) | HTR2BHRH1KCNH2ALDH1A1LMNA | |
| SCHEMBL1918427 | 0.88 | HTR2B (0.45) | HTR2BHRH1KCNH2ALDH1A1LMNA | |
| SCHEMBL1918425 | 0.88 | HTR2B (0.45) | HTR2BHRH1KCNH2ALDH1A1LMNA | |
| SCHEMBL1918556 | 0.83 | SRD5A1 (0.37) | HTR2BHRH1KCNH2ALDH1A1LMNA | |
| SCHEMBL4364540 | 0.83 | SRD5A1 (0.37) | HTR2BHRH1KCNH2ALDH1A1LMNA | |
| SCHEMBL1918552 | 0.83 | SRD5A1 (0.37) | HTR2BHRH1KCNH2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3081213-B1 | TRICYCLIC COMPOUND | KYOWA KIRIN CO LTD (JP) | 2020-04-01 | — | — | EP | disclosed |
| US-9475805-B2 | Tricyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-10-25 | — | — | US | disclosed |
| EP-3081213-A1 | TRICYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2016-10-19 | — | — | EP | disclosed |
| US-20150291587-A1 | TRICYCLIC COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2015-10-15 | — | — | US | disclosed |
| EP-1988091-B1 | TRICYCLIC COMPOUNDS | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-06-10 | — | — | EP | disclosed |
| US-20130267711-A1 | TRICYCLIC COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-10-10 | — | — | US | disclosed |
| US-8486980-B2 | Tricyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-07-16 | — | — | US | disclosed |
| US-8242151-B2 | Tricyclic compounds | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20110201640-A1 | TRICYCLIC COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2327690-A1 | TRICYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-20090176760-A1 | TRICYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1988091-A1 | TRICYCLIC COMPOUNDS | Kyowa Hakko Kogyo Co., Ltd (JP) | 2008-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291587-A1 | TRICYCLIC COMPOUND | PPARA, PPARG, PPARD | HTR2B 836/4885HRH1 1435/4885KCNH2 2044/4885 |
| US-20130267711-A1 | TRICYCLIC COMPOUND | PPARA, PPARG, PPARD | HTR2B 836/4885HRH1 1435/4885KCNH2 2044/4885 |
| US-20110201640-A1 | TRICYCLIC COMPOUND | PPARG, PPARA, PPARD | HTR2B 766/4885HRH1 1723/4885KCNH2 1629/4885 |
| US-20090176760-A1 | TRICYCLIC COMPOUNDS | PPARG, PPARD, PPARA | HTR2B 897/4885HRH1 1267/4885KCNH2 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.